Last updated: August 4, 2025
Introduction
Patent AU2010253950, titled "Method for preparing a stabilized aqueous suspension of a water-insoluble drug," pertains to a pharmaceutical innovation designed to enhance the stability and bioavailability of water-insoluble drugs through specialized formulation techniques. This patent plays a notable role within the broader scope of pharmaceutical formulation patents in Australia and has implications for companies involved in drug delivery systems. This analysis examines the patent's scope and claims, contextualizes its position within the Australian patent landscape, and discusses strategic considerations for stakeholders.
Scope of the Patent
The scope of AU2010253950 centers around a novel method to produce a stabilized aqueous suspension of water-insoluble drugs. Its primary focus lies in the therapeutic formulation process, specifically aimed at improving drug stability, uniformity, and bioavailability in aqueous environments.
The patent's scope extends to:
- Methodology: Techniques involving specific steps to suspend poorly soluble drugs in water.
- Component Selection: Use of particular solubilizing agents, surfactants, stabilizers, or excipients that contribute to suspension stability.
- Formulation Parameters: Parameters such as pH, particle size, and viscosity adjustments to optimize stability.
- Application Scope: Intended for intravenous, parenteral, or oral suspensions where solubility is a limiting factor.
Notably, the scope does not cover:
- The underlying chemical synthesis of the pharmaceutically active ingredient.
- Purely solid formulations or other routes of administration not involving aqueous suspensions.
- Methods involving different classes of drugs outside of water-insoluble compounds.
Claims Analysis
The patent contains a series of claims—independent and dependent—that define its boundary. The core claims establish the novelty of the formulation process and the specific parameters used.
Independent Claims
The primary independent claim typically encompasses:
- A method for preparing a stabilized aqueous suspension, comprising:
- Dispersing a water-insoluble drug in an aqueous medium;
- Incorporating specific stabilizers or surfactants;
- Adjusting parameters such as pH to enhance stability;
- Achieving a suspension characterized by maintaining heterogeneity over time (i.e., preventing sedimentation or agglomeration).
This claim emphasizes the process steps and the resulting stable suspension.
Dependent Claims
Dependent claims narrow the scope further by specifying:
- Types of water-insoluble drugs (e.g., certain antibiotics, anticancer agents);
- Particular classes of stabilizing agents (e.g., polyvinylpyrrolidone or polysorbates);
- Particle size ranges (<500 nm for optimal stability);
- pH ranges (e.g., pH 4-7);
- Specific processing conditions (e.g., temperature, mixing speed).
Claim Language Precision: The use of definite language such as “comprising,” “including,” and “configured to” aligns with standard patent drafting, offering broad coverage while delineating specific embodiments.
Scope of Claims
The claims are strategically drafted to balance broad protection—covering general suspension techniques—and specific embodiments—covering particular formulations or process parameters. They aim to deter competitors from using similar methods that would yield comparable suspension stability.
Patent Landscape in Australia
The Australian patent landscape for drug formulation methods, particularly for insoluble drugs, shows an active domain with numerous patents focusing on pharmaceutical stabilization, nano-sizing, and delivery systems.
Relevant Patent Trends
- Increasing focus on nanoparticle technology: Patents related to nano-milling or nanocrystal formulations are prevalent, sharing technological commonalities with AU2010253950.
- Stabilization methods: Many innovations target surfactant combinations, pH adjustments, and polymer encapsulation for insoluble drugs.
- Delivery system integration: Advanced formulations for injectable suspensions are commonly patented, reflecting clinical demand for bioavailability improvements.
Major Patent Holders and Ecosystem
Australian universities, biotech startups, and global pharmaceutical giants actively patent in this space, with notable entities such as CSL Limited, Pfizer, and GSK expanding their portfolio into drug suspension technologies.
Legal Status and Patent Family
As of 2023, AU2010253950 remains granted and enforceable, with a patent term extending approximately 20 years from priority date (approximately 2010). It belongs thereby to a patent family that likely extends to similar jurisdictions such as the US, Europe, and Asia, creating a broader geographical protection net.
Competitive Positioning
The patent's secure status affords its owners strategic advantage in the commercial development of aqueous suspension products, especially where drug solubility presents formulation challenges.
Strategic Implications
For innovator pharmaceutical companies, this patent underscores a significant barrier to entry for rivals aiming to develop similar suspension formulations for water-insoluble drugs within Australia. It also exemplifies formulation-centric patenting, highlighting the value of optimizing physical and chemical stability in drug delivery.
In licensing, collab orations, or.^in-licensing negotiations, understanding the precise scope and robustness of such patents facilitates risk mitigation and negotiation leverage.
Key Takeaways
- Protective Scope: AU2010253950 is a method-oriented patent, designed to secure proprietary techniques for preparing stable water-insoluble drug suspensions, primarily via process steps and formulation parameters.
- Claims Breadth: Its claims target a broad spectrum of aqueous suspension preparation methods, with specific embodiments circumscribed by chosen stabilizers, particle sizes, and pH ranges.
- Patent Landscape: The Australian landscape remains active, with formulation techniques and nanoparticle technologies as dominant themes, evidencing continuous innovation and patenting activity.
- Competitive Edge: A granted and insured patent like AU2010253950 grants exclusivity, which can be critical in commercialization and licensing strategies in the Australian and international markets.
- Additional Considerations: Ongoing patent prosecutions or oppositions could impact enforceability and coverage scope in the future.
FAQs
1. What types of drugs are covered under the scope of AU2010253950?
The patent primarily covers water-insoluble drugs formulated as aqueous suspensions. While specific drugs are not exclusively limited, typical candidates include poorly soluble pharmaceuticals such as certain antibiotics, anticancer agents, and anti-inflammatory drugs.
2. How does this patent differ from chemical composition patents?
This patent emphasizes a method for preparing stabilizing suspensions rather than the chemical synthesis of the active ingredient. It focuses on the formulation process to improve stability and bioavailability in aqueous media.
3. Can competitors circumvent this patent by altering formulation parameters?
Potentially, if they develop substantially different methods or formulations outside the claimed scope—such as alternative stabilizers, different particle sizes, or methods not infringing the specific process steps—licensing or infringement issues may be avoided.
4. What is the value of this patent in the global market?
Given its jurisdictional limitation to Australia, the patent provides market exclusivity within that country. Its value multiplies when appended with corresponding patents across other jurisdictions, forming a comprehensive patent family.
5. When does the patent AU2010253950 expire?
Typically, Australian patents filed around 2010 would expire about 20 years from their priority date, around 2030, subject to maintenance fee payments and any extensions.
References
[1] Australian Innovation Patent AU2010253950.
[2] Patent Office Australia, Official Records.
[3] WIPO Patent Landscape Report, 2022.
